You are here

  • Home
  • Archive
  • Volume 81, Issue 9
  • Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease

Article info

Article menu
Osteoporosis
Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease

Authors

  • Edgar Wiebe Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Dörte Huscher Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Désireé Schaumburg Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Andriko Palmowski Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Sandra Hermann Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Thomas Buttgereit Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Berlin, Germany Institute of Allergology, Charité, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Robert Biesen Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Gerd-Rüdiger Burmester Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Yannick Palmowski Center for Musculoskeletal Surgery, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Maarten Boers Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands PubMed articlesGoogle scholar articles
  • John H Stone Vasculitis and Glomerulonephritis Center, Rheumatology, Immunology and Allergy Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Christian Dejaco Rheumatology, Medical University of Graz, Graz, Austria Rheumatology, Brunico Hospital (SABES-ASDAA), Brunico, Italy PubMed articlesGoogle scholar articles
  • Frank Buttgereit Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Frank Buttgereit, Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; frank.buttgereit{at}charite.de
View Full Text

Citation

Wiebe E, Huscher D, Schaumburg D, et al
Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease
Annals of the Rheumatic Diseases 2022;81:1313-1322.

Publication history

  • Received February 11, 2022
  • Accepted May 8, 2022
  • First published June 9, 2022.
Online issue publication 
August 11, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.